U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both conditions.

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...